ReviewCurrent oncology (Toronto, Ont.)2024
Current Concepts in the Treatment of Giant Cell Tumor of Bone: An Update.
Review in Current oncology (Toronto, Ont.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 18 citations in OpenAlex.
- Optimal management of giant cell tumor in the tibial plateau: A case report on curettage and cement reinforcement.Radiology case reports · 2026Article
- Secondary Malignant Transformation of Giant Cell Tumor of Bone Nine Years After Initial Curettage: A Case Report and Literature Review.Reports (MDPI) · 2026Article
- Giant cell tumor of bone: exploring HtrA1 as a potential predictor of recurrence.Archives of orthopaedic and trauma surgery · 2026Article
- Giant Cell Tumor of the Sacrum: A Narrative Review of Management Challenges and Modalities.Healthcare (Basel, Switzerland) · 2026Review
- Combined Post-operative Denosumab and Oral Bisphosphonate Therapy Following Resection of Spinal Giant Cell Tumor: A Case Report.Journal of orthopaedic case reports · 2026Article
- Denosumab combined with curettage after surgical dislocation of the hip in the treatment of giant cell tumors of bone in the femoral head and neck region: a single-center retrospective study.BMC musculoskeletal disorders · 2026Article
- Efficacy of microwaveAmerican journal of translational research · 2026Article
- Metachronous multicentric giant cell tumor of bone with pulmonary metastases: a case report with 20-year follow-up.Frontiers in oncology · 2026Article
- Surgically Treated Benign Bone Tumors and Tumor-like Conditions in the Pediatric Population-A 10-Year Institutional Experience.Children (Basel, Switzerland) · 2025Article
- Efficacy and safety of curettage with bone grafting combined with denosumab in the treatment of distal radius giant cell tumor of bone.Medicine · 2025Observational
- Clinical pathological characteristics correlation ofTranslational cancer research · 2025Article
- Treatment of Extraosseous Giant Cell Tumor of Bone and Calcitriol-Mediated Hypercalcemia With Denosumab in Paget Disease.JCEM case reports · 2025Article
- Preoperative denosumab combined with microwave ablation for joint preservation in advanced giant cell tumor of bone: a retrospective study.Journal of orthopaedic surgery and research · 2025Article
- Repetitive Transcranial Magnetic Stimulation: Is it an Effective Treatment for Cancer Pain?Pain and therapy · 2025Review
- Multidisciplinary marvel: surgical management of aggressive giant cell tumor around the knee in pregnancy: a case report.Journal of surgical case reports · 2025Article
- Article
- Pathological predictors for curettage and cementation outcome in proximal tibial giant cell tumors.Bioinformation · 2025Article
- Disturbed glycolipid metabolism activates CXCL13-CXCR5 axis in senescent TSCs to promote heterotopic ossification.Cellular and molecular life sciences : CMLS · 2024Article
- Giant Cell Tumor of the Proximal Fibula in a 15-year-old Female: A Review and Case Report.In vivo (Athens, Greece)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Curettage is recommended for the treatment of Campanacci stages 1-2 giant cell tumor of bone (GCTB) in the extremities, pelvis, sacrum, and spine, without preoperative denosumab treatment. In the distal femur, bone chips and plate fixation are utilized to reduce damage to the subchondral bone and prevent pathological fracture, respectively. For local recurrence, re-curettage may be utilized when feasible. En bloc resection is an option for very aggressive Campanacci stage 3 GCTB in the extremities, pelvis, sacrum, and spine, combined with 1-3 doses of preoperative denosumab treatment. Denosumab monotherapy once every 3 months is currently the standard strategy for inoperable patients and those with metastatic GCTB. However, in case of tumor growth, a possible malignant transformation should be considered. Zoledronic acid appears to be as effective as denosumab; nevertheless, it is a more cost-effective option. Therefore, zoledronic acid may be an alternative treatment option, particularly in developing countries. Surgery is the mainstay treatment for malignant GCTB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.